Abstract:Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Amphotericin B colloidal dispersion (ABCD) has less renal toxicity than traditional amphotericin B. There is no evidence of ABCD made in China in patients with hematologic diseases complicated with IFD. Aims: The purpose of this study was to evaluate the efficacy and safety of ABCD made in China in the treatment of invasive aspergillosis in patients with hematologic diseases. Methods: In this multi-center, one-arm study, 65 patients with invasive aspergillosis were enrolled to receive ABCD antifungal therapy with a treatment of 28 days. The primary endpoint was the treatment response rate, and the secondary endpoint was the incidence of ABCD related adverse events. Results: By September 2022, a total of 22 patients were enrolled for interim analysis. Safety was assessed in all enrolled patients, and efficacy was assessed in 16 patients (72.7%) who were treated for at least 1 week. The median age was 42.5 years (range 18-68), and the underlying disease was mainly acute myeloid leukemia (n= 19,86.4%). Most of the enrolled patients showed characteristic pulmonary aspergillus infection (n=21, 95.5%), and Aspergillus was detected by microbiology in 2 cases (9.1%). In this study, 81.8% (n=18) patients had a history of antifungal therapy, and were switched to ABCD after treatment failure (n= 6, 27.3%) or prevention breakthrough (n=12, 54.5%). The median treatment time of ABCD was 16 (range 1-28) days, and the average daily dose of ABCD was (2.3±0.7) mg·kg-1·d-1. The effective rate was 81.3% (13/16). 9.1% (n=2) of patients stopped treatment early due to infusion reaction, suggesting that attention should be paid to the prevention and treatment of infusion reaction in clinical treatment. Grade 3/4 adverse events included fever (4.5%), hypokalemia (31.8%), and increased alanine aminotransferase (9.1%), without grade 3/4 increased creatinine, indicating low renal toxicity of ABCD. Summary/Conclusion: ABCD made in China has shown good clinical efficacy and acceptable toxicity in the treatment of invasive aspergillus disease, especially low renal toxicity, which provides a new choice for antifungal therapy. Keywords: Hematological malignancy, Invasive aspergillosis, Clinical outcome, Amphotericin

Clinical evaluation of intravenous amphoterin B colloidal dispersion for the treatment of 30 patients with invasive fungal infections

Comparative Evaluation of ATB FUNGUS 3 Procedure and CLSI M27-A2 Broth Microdilution Method for Antifungal Susceptibility Testing of Pathogenic Yeasts

[Clinical Study of Amphotericin B in the Treatment of Invasive Fungal Infection in 111 Hematological Disorder Patients with Neutrocytopenia].

Pharmacokinetics and Safety of Single-Dose Amphotericin B Colloidal Dispersion in Healthy Chinese Subjects and Population Pharmacokinetic/Pharmacodynamic Analysis to Inform Clinical Efficacy in Invasive Infections Caused by Candida albicans

Amphotericin B in the Treatment of 152 Patients with Invasive Fungal Infection

Pb2589: efficacy and safety of abcd in the treatment of invasive aspergillosis in patients with hematologic diseases

Treatment of cryptococcal meningitis with low-dose amphotericin B and flucytosine.

[Clinical analysis of amphotericin B cholesteryl sulfate complex for injection in the treatment of invasive fungal disease for patients with hematological malignancies in 30 cases].

Efficacy and Safety of Domestic Amphotericin B in Preemptive Therapy of Pulmonary Invasive Fungal Infection in Hematological Disorder Patients

[Efficacy and Safety of Low-dose Amphotericin B in Different Antifungal Strategies for Treatment of Invasive Fungal Disease in Patients with Hematological Malignancies].

Liposomal Amphotericin B in Treating Deep Fungal Infections:A Clinical Study on the Efficacy and Safety

[Evaluation of Low-Dose Amphotericin B and Flucytosine in the Treatment of Cryptococcal Meningitis].

Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections

Pharmacokinetic and pharmacodynamic profiling of generic amphotericin B colloidal dispersion in a rat model of invasive candidiasis

Analysis of the Efficacy and Adverse Reactions of Amphotericin B at different Doses

The use of amphotericin B in hematologic malignancy children with invasive fungal infections

Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study

A clinical analysis of micafungin treatment in hematological malignancy complicated with invasive fungal diseases

Clinical Research of Fungal Infection in 296 AIDS Patients

Safety of different amphotericin B formulations among AIDS patients with invasive fungal disease: a retrospective observational study

[Clinical efficacy and safety of liposomal amphotericin B in the salvage treatment of invasive fungal disease in patients with hematological diseases]